El Tahir Omaima, Vrijlandt Sanne, de Jongh Jelle, de Jonge Rogier C J, Goei Sui Lin, Pronk Jeroen, van Furth Anne Marceline
Department of Pediatric Infectious Diseases and Immunology, Amsterdam UMC Locatie VUmc, Amsterdam, Netherlands
Erasmus MC Sophia, Rotterdam, Netherlands.
BMJ Paediatr Open. 2025 Aug 13;9(1):e003536. doi: 10.1136/bmjpo-2025-003536.
To determine healthcare and productivity loss costs among young adult survivors of childhood bacterial meningitis (BM).
In this cross-sectional study, online versions of the Institute for Medical Technological Assessment (iMTA) Medical Consumption Questionnaire and the iMTA Productivity Costs Questionnaire were used to measure healthcare consumption and productivity loss costs in young adult survivors of childhood BM. Mean healthcare and productivity loss costs were calculated and the differences in costs across subgroups based on age at onset, sex and causative pathogens were investigated.
A total of 454 patients were included in the cost analysis of healthcare utilisation and a total of 471 patients were included in the cost analysis of productivity losses. The 3-month mean societal cost per patient amounted to €4985.32 (median €1363.71, IQR €576.04-€2948.67), of which €4790.84 (median €1125.90, IQR €271.20-€2489.54) was due to productivity losses. Productivity loss costs were significantly higher in survivors of childhood BM caused by compared with survivors of childhood BM caused by .
This study highlights the potential significant economic burden in young survivors of childhood BM and emphasises the possible impact of very long-term sequelae. In particular, very long-term sequelae of BM contribute to indirect costs. To the best of our knowledge, this is the first study to investigate the societal costs of childhood BM over a two-decade follow-up period. Further research into societal costs in young adult survivors of neonatal meningitis is needed to provide additional insights into the economic burden of childhood BM.
确定儿童细菌性脑膜炎（BM）成年幸存者的医疗保健和生产力损失成本。
在这项横断面研究中，使用了医学技术评估研究所（iMTA）医疗消费问卷和iMTA生产力成本问卷的在线版本，以测量儿童BM成年幸存者的医疗消费和生产力损失成本。计算了平均医疗保健和生产力损失成本，并调查了基于发病年龄、性别和致病病原体的亚组间成本差异。
共有454名患者纳入医疗保健利用成本分析，共有471名患者纳入生产力损失成本分析。每位患者3个月的平均社会成本为4985.32欧元（中位数1363.71欧元，四分位距576.04 - 2948.67欧元），其中4790.84欧元（中位数1125.90欧元，四分位距271.20 - 2489.54欧元）是由于生产力损失。与由[未提及的病原体]引起的儿童BM幸存者相比，由[未提及的病原体]引起的儿童BM幸存者的生产力损失成本显著更高。
本研究强调了儿童BM年轻幸存者潜在的重大经济负担，并强调了非常长期后遗症的可能影响。特别是，BM的非常长期后遗症导致间接成本。据我们所知，这是第一项在长达二十年的随访期内调查儿童BM社会成本的研究。需要对新生儿脑膜炎成年幸存者的社会成本进行进一步研究，以提供关于儿童BM经济负担的更多见解。
